Parveen Rasna, Thakur Arpan Kumar, Srivastav Sharad, Puraswani Mamta, Srivastava Ashish Kumar, Chakrabarti Arunaloke, Rodrigues Camilla, Ray Pallab, Biswal Manisha, Taneja Neelam, Wattal Chand, Venkatesh Vimala, Sethuraman Nandini, Bhattacharya Sanjay, Nag Vijaya Lakshmi, Tak Vibhor, Behera Bijayini, Balaji Veeraragavan, Ray Raja, Singh Sanjeev K, Mukhopadhyay Chiranjay, Michael Joy Sarojini, Fomda Bashir Ahmad, Karuna Tadepalli, Deotale Vijayshri, Das Padma, Prasad Amber, Majumder Tapan, Gupta Puneet Kumar, Padmaja Kanne, Mathur Purva
Department of Laboratory Medicine, Jai Prakash Narayan Apex Trauma Center, All India Institute of Medical Sciences, Delhi, India.
Department of Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Lancet Glob Health. 2025 Sep;13(9):e1564-e1573. doi: 10.1016/S2214-109X(25)00221-9.
Central line-associated bloodstream infections (CLABSIs) are preventable health-care-associated infections (HAIs) that cause considerable morbidity and mortality. Understanding the epidemiology of CLABSIs through large, quality-assured, hospital-based datasets could help to enable development of preventive protocols suited to specific health-care systems. We aimed to describe the profile of CLABSIs in intensive care units (ICUs) at tertiary care centres in India.
We obtained data from around 200 adult, paediatric, and neonatal ICUs at 54 hospitals reporting to the Indian HAI surveillance network over a period of 7 years. All hospitals conducted bloodstream infection surveillance using standardised protocols. Cases of CLABSI were recorded on standard case report forms and were submitted to the HAI surveillance database. Denominator data (patient-days and central line-days) were entered monthly. Data quality was evaluated by a central team at the All-India Institute of Medical Sciences (New Delhi, India). We calculated CLABSI rates per 1000 central line-days and central-line utilisation ratio (CLUR) by year and ICU type (adult, paediatric, or neonatal). Commonly reported pathogens were ranked and the proportions of priority pathogens showing antimicrobial resistance were also estimated for each 1-year period and each ICU type.
During the surveillance period from May 1, 2017 to April 30, 2024, 8629 laboratory-confirmed CLABSI events, 3 054 124 patient-days, and 977 052 central line-days were recorded. The overall pooled CLABSI rate was 8·83 per 1000 central line-days and the pooled CLUR was 0·32. CLABSI rates were 8·68 per 1000 central line-days in adult ICUs (CLUR 0·38), 6·71 per 1000 central line-days in paediatric ICUs (0·27), and 13·86 per 1000 central line-days in neonatal ICUs (0·11). Among the total 10 042 pathogens reported, 8981 (89·4%) were bacterial and 1061 (10·6%) were fungal; Klebsiella pneumoniae (2294 [22·8%] isolates) and Acinetobacter baumannii (2047 [20·4%] isolates) were the most frequently reported for each ICU type. Among isolates tested, resistance to carbapenem was found to be highest in A baumannii (1607 [87·1%] resistant isolates of 1846 tested) and K pneumoniae (1589 [77·7%] of 2046).
This is the first large-scale observational study and standardised surveillance report of CLABSI in India. The data generated from this network provide a valuable opportunity for a quality improvement-based approach for the reduction of CLABSI.
US Centers for Disease Control and Prevention cooperative agreement with the All-India Institute of Medical Sciences (New Delhi, India).
For the Hindi translation of the abstract see Supplementary Materials section.
中心静脉导管相关血流感染(CLABSI)是可预防的医疗保健相关感染(HAI),会导致相当高的发病率和死亡率。通过大规模、质量有保证的基于医院的数据集了解CLABSI的流行病学情况,有助于制定适合特定医疗保健系统的预防方案。我们旨在描述印度三级医疗中心重症监护病房(ICU)中CLABSI的情况。
我们从向印度HAI监测网络报告的54家医院的约200个成人、儿科和新生儿ICU获取了7年期间的数据。所有医院都使用标准化方案进行血流感染监测。CLABSI病例记录在标准病例报告表上,并提交到HAI监测数据库。分母数据(患者住院日和中心静脉导管留置日)每月录入。数据质量由全印度医学科学研究所(印度新德里)的一个中心团队进行评估。我们按年份和ICU类型(成人、儿科或新生儿)计算每1000个中心静脉导管留置日的CLABSI发生率和中心静脉导管使用率(CLUR)。对常见报告的病原体进行排名,并估计每个1年期间和每种ICU类型中显示抗菌药物耐药性的重点病原体比例。
在2017年5月1日至2024年4月30日的监测期间,记录了8629例实验室确诊的CLABSI事件、3054124个患者住院日和977052个中心静脉导管留置日。总体汇总的CLABSI发生率为每1000个中心静脉导管留置日8.83例,汇总的CLUR为0.32。成人ICU的CLABSI发生率为每1000个中心静脉导管留置日8.68例(CLUR 0.38),儿科ICU为每1000个中心静脉导管留置日6.71例(0.27),新生儿ICU为每1000个中心静脉导管留置日13.86例(0.11)。在报告的总共10042种病原体中,8981种(89.4%)为细菌,1061种(10.6%)为真菌;每种ICU类型中报告最频繁的是肺炎克雷伯菌(2294株[22.8%]分离株)和鲍曼不动杆菌(2047株[20.4%]分离株)。在检测的分离株中,鲍曼不动杆菌(1846株中1607株[87.1%]耐药分离株)和肺炎克雷伯菌(2046株中1589株[77.7%])对碳青霉烯类药物的耐药性最高。
这是印度首次关于CLABSI的大规模观察性研究和标准化监测报告。该网络生成的数据为基于质量改进的方法来降低CLABSI提供了宝贵机会。
美国疾病控制与预防中心与全印度医学科学研究所(印度新德里)的合作协议。
摘要的印地语翻译见补充材料部分。